GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results
GSK shares fell 1.7% to 1,817 pence in London Friday, extending a three-day slide and closing 11.7% below their December peak. Trading volume surged to 12.6 million shares. Filings showed senior executives reinvested dividends into shares and U.S. ADSs. Investors are awaiting GSK’s full-year results and U.S. drug-approval updates in early February.